Neurophet receives FDA 510(k) Clearance for Neurophet AQUA

Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA

Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance Introduces 'Neurophet AQUA AD,' a

Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA'

New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities

Brain-computer interface to control digital devices using thoughts: The European Patent Office has announced that Australian researchers have been selected as finalists for the European Inventor Award 2023

GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025

YONGIN, South Korea , Feb. 11, 2025 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company,

Chula Launches the Latest Parkinson's Gloves to Reduce Tremors

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™

** IND submitted to the FDA showing significantly improved patient condition when administered within 70

BTL Unveils EXOMIND: A New Era in Mental Wellness

The breakthrough ExoTMS™ technology stimulates key brain areas, boosts neuroplasticity, and strengthens

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that